Bajaj Finance Raises Rs 17,500 Crore via QIP and Preferential Warrants

Bajaj Finance, one of India's largest lenders, has approved a fund raise of up to Rs 17,500 crore, which includes Rs 11,700 crore through QIP and Rs 5,800 crore through preferential warrants. This move is expected to strengthen its capital base and support continued balance-sheet expansion.

The company delivered strong Q2FY27 growth, with customer franchise up 16.5% YoY to 128.9 million, AUM up 26.5% YoY to Rs 5.85 lakh crore, and new loans book increasing 11% YoY, despite festive-season timing impact on new loan bookings.

Molbio Diagnostics, a leading player in the point-of-care diagnostics market, has a proprietary Truenat platform that is expected to drive growth. The platform offers portable, battery-operated molecular testing with around 60-minute turnaround and minimal infrastructure.

Read More: Indian Railways to Launch Second Vande Bharat Sleeper Train, Reducing Bengaluru-Mumbai Journey

With 12,500+ Truenat devices across 90+ countries and 43 assays covering 30 diseases. Molbio has significant growth potential in the expanding point-of-care infectious-disease market. Diversification beyond TB, international adoption, and new assays are expected to support sustained growth.

Expansion into digital pathology and advanced imaging through Prognosys/OptraSCAN is expected to broaden Molbio's addressable market. The Motilal Oswal Wealth Management Research Desk has recommended Molbio Diagnostics as a top stock to buy for the week starting October 12. 2026, citing its expanding installed base, assay menu, and global reach.

AIQ, a leading AI-powered diagnostic platform, has also partnered with Molbio Diagnostics to enhance its point-of-care diagnostics capabilities. This partnership is expected to further boost Molbio's growth prospects in the point-of-care diagnostics market.

Also Read: Man Wins Tax Case After Tribunal Verifies Commercial Nature of Dhakoli, Zirakpur Property

As the market continues to evolve, Molbio Diagnostics is well-positioned to capitalize on the growing demand for point-of-care diagnostics. With its proprietary Truenat platform, expanding installed base, and diversification plans, the company is expected to deliver strong growth in the coming years.

Bajaj Finance, on the other hand, has a strong track record of delivering growth and is expected to continue its momentum with the recent fund raise. The company's expanding balance sheet and continued balance-sheet expansion are expected to support its growth prospects.

Overall, both Bajaj Finance and Molbio Diagnostics are expected to deliver strong growth in the coming years, driven by their expanding installed bases, diversification plans, and growing demand for point-of-care diagnostics.